LY 227942

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529173

CAS#: 116817-14-2

Description: LY 227942 is a bioactive chemical.

Chemical Structure

img
LY 227942
CAS# 116817-14-2
Instruction

Theoretical Analysis

MedKoo Cat#: 529173
Name: LY 227942
CAS#: 116817-14-2
Chemical Formula: C20H21NO5S
Exact Mass: 387.11
Molecular Weight: 387.450
Elemental Analysis: C, 62.00; H, 5.46; N, 3.62; O, 20.65; S, 8.27

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: LY 227942

IUPAC/Chemical Name: 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, ethanedioate (1:1)

InChi Key: NMLRFGBDXFMJJM-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H19NOS.C2H2O4/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16;3-1(4)2(5)6/h2-10,13,17,19H,11-12H2,1H3;(H,3,4)(H,5,6)

SMILES Code: CNCCC(OC1=C2C=CC=CC2=CC=C1)C3=CC=CS3.O=C(O)C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 387.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yassin M, Oron A, Robinson D. Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. Clin Exp Rheumatol. 2018 Oct 30. [Epub ahead of print] PubMed PMID: 30418116.

2: Yamashita T, Tsuda M, Tozaki-Saitoh H, Inoue K. [Green Pharma: A New Strategy for Drug Discovery in Academia by Targeting Glial Cells and ATP Receptors]. Yakugaku Zasshi. 2018;138(8):1027-1031. doi: 10.1248/yakushi.17-00211-1. Review. Japanese. PubMed PMID: 30068843.

3: Hu D, Wurster S. Hyponatremia Induced by Duloxetine: A Case Report. Consult Pharm. 2018 Aug 1;33(8):446-449. doi: 10.4140/TCP.n.2018.446. PubMed PMID: 30068437.

4: Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203. doi: 10.1159/000491524. Epub 2018 Jul 17. Review. PubMed PMID: 30016772.

5: Kim EJ, Felsovalyi K, Young LM, Shmelkov SV, Grunebaum MF, Cardozo T. Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues. Psychopharmacology (Berl). 2018 Sep;235(9):2643-2650. doi: 10.1007/s00213-018-4958-9. Epub 2018 Jul 1. PubMed PMID: 29961917; PubMed Central PMCID: PMC6132670.

6: Guo MY, Etminan M, Procyshyn RM, Kim DD, Samii A, Kezouh A, Carleton BC. Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study. J Clin Psychopharmacol. 2018 Aug;38(4):349-356. doi: 10.1097/JCP.0000000000000911. PubMed PMID: 29901567.

7: Mizutani H, Sakakibara F, Komuro M, Sasaki E. TAS-303, a Novel Selective Norepinephrine Reuptake Inhibitor that Increases Urethral Pressure in Rats, Indicating Its Potential as a Therapeutic Agent for Stress Urinary Incontinence. J Pharmacol Exp Ther. 2018 Aug;366(2):322-331. doi: 10.1124/jpet.118.248039. Epub 2018 Jun 6. PubMed PMID: 29875227.

8: Tawfik MK, Helmy SA, Badran DI, Zaitone SA. Neuroprotective effect of duloxetine in a mouse model of diabetic neuropathy: Role of glia suppressing mechanisms. Life Sci. 2018 Jul 15;205:113-124. doi: 10.1016/j.lfs.2018.05.025. Epub 2018 May 12. PubMed PMID: 29763613.

9: Balaha M, Kandeel S, Kabel A. Phloretin either alone or in combination with duloxetine alleviates the STZ-induced diabetic neuropathy in rats. Biomed Pharmacother. 2018 May;101:821-832. doi: 10.1016/j.biopha.2018.02.135. Epub 2018 Mar 22. PubMed PMID: 29635891.

10: Cozart B, Diaz Vera J, Denham JD, Whiting WL. Treatment of Depression With Duloxetine in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes. Clin Neuropharmacol. 2018 May/Jun;41(3):103-105. doi: 10.1097/WNF.0000000000000277. PubMed PMID: 29596118.

11: Siddiqui SH, Memon NA, Shanker R. Drug-induced movement disorder and confusion associated with duloxetine. BMJ Case Rep. 2018 Mar 28;2018. pii: bcr-2016-216746. doi: 10.1136/bcr-2016-216746. PubMed PMID: 29592972.

12: Li X, Zhu L, Zhou C, Liu J, Du H, Wang C, Fang S. Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis. PLoS One. 2018 Mar 20;13(3):e0194501. doi: 10.1371/journal.pone.0194501. eCollection 2018. PubMed PMID: 29558528; PubMed Central PMCID: PMC5860757.

13: Kiso T, Moriyama A, Furutani M, Matsuda R, Funatsu Y. Effects of pregabalin and duloxetine on neurotransmitters in the dorsal horn of the spinal cord in a rat model of fibromyalgia. Eur J Pharmacol. 2018 May 15;827:117-124. doi: 10.1016/j.ejphar.2018.03.011. Epub 2018 Mar 9. PubMed PMID: 29530591.

14: Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018 Feb 28;2:CD010292. doi: 10.1002/14651858.CD010292.pub2. Review. PubMed PMID: 29489029; PubMed Central PMCID: PMC5846183.

15: Thorpe J, Shum B, Moore RA, Wiffen PJ, Gilron I. Combination pharmacotherapy for the treatment of fibromyalgia in adults. Cochrane Database Syst Rev. 2018 Feb 19;2:CD010585. doi: 10.1002/14651858.CD010585.pub2. Review. PubMed PMID: 29457627.

16: Minguez L, Bureau R, Halm-Lemeille MP. Joint effects of nine antidepressants on Raphidocelis subcapitata and Skeletonema marinoi: A matter of amine functional groups. Aquat Toxicol. 2018 Mar;196:117-123. doi: 10.1016/j.aquatox.2018.01.015. Epub 2018 Jan 31. PubMed PMID: 29367071.

17: Dunlop BW, Cole SP, Nemeroff CB, Mayberg HS, Craighead WE. Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder. J Affect Disord. 2018 Mar 15;229:111-119. doi: 10.1016/j.jad.2017.12.035. Epub 2017 Dec 27. PubMed PMID: 29306690; PubMed Central PMCID: PMC5807140.

18: Masuda R, Ajimi J, Murata T. Pharmacotherapy for Neuropathic Pain in Japan. J Nippon Med Sch. 2017;84(6):258-267. doi: 10.1272/jnms.84.258. Review. PubMed PMID: 29279555.

19: Revol R, Rault C, Polard E, Bellet F, Guy C. [Hyponatremia associated with SSRI/NRSI: Descriptive and comparative epidemiological study of the incidence rates of the notified cases from the data of the French National Pharmacovigilance Database and the French National Health Insurance]. Encephale. 2018 Jun;44(3):291-296. doi: 10.1016/j.encep.2017.09.003. Epub 2017 Dec 14. French. PubMed PMID: 29248119.

20: Nedahl M, Johansen SS, Linnet K. Reference Brain/Blood Concentrations of Citalopram, Duloxetine, Mirtazapine and Sertraline. J Anal Toxicol. 2018 Apr 1;42(3):149-156. doi: 10.1093/jat/bkx098. PubMed PMID: 29244076.